Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II randomized, double-blind, placebo-controlled trial of neoadjuvant
artesunate given orally as a dose of 200 mg once a day for 14 days to patients with
histologically confirmed Stage II/III colorectal cancer (CRC) awaiting surgical treatment
with curative intent.
Phase:
Phase 2
Details
Lead Sponsor:
The 108 Military Central Hospital
Collaborator:
Institute of Tropical Medicine, University of Tuebingen